Stocks to Buy
Stocks to Sell
Stock Market Today
401k & Investing Tips
Financial Advisor Center
Trade of the Day
How to Trade Options
Gadgets, Smartphones & Tech
Meet Our Experts
Read complete bio
Xerox: Making Progress on the Comeback Path
Apr. 27, 2012, 10:50 am EDT – Its transition to a digital world is steadily taking shape. Wall Street isn't paying much attention, but XRX could be a long-term turnaround bet.
Cue the Biotech M&A Attack!
Apr. 20, 2012, 9:58 am EDT – A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.
ConocoPhillips’ Happy Divorce
Apr. 16, 2012, 10:34 am EDT – The spin-off of the refining operations is good news for investors.
Here Comes a Bidding War for Amylin
Apr. 2, 2012, 7:15 am EDT – Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.
What the Bears Miss About Las Vegas Sands
Mar. 23, 2012, 10:29 am EDT – Investors under-appreciate the growth opportunities in Macau and Singapore.
Pony Up for American Express
Mar. 16, 2012, 9:05 am EDT – Stress test winner American Express has it all: Solid financial footing, growing revenues and profits, a newly raised dividend -- and an alluring valuation.
This Small-Cap Telecom Deserves Your Attention
Mar. 9, 2012, 8:55 am EDT – Cincinnati Bell is mulling a spin-off that would unlock a lot of value. It's attracting some big-money interest -- and you should be watching it, too.
Why Starbucks Is Still Steaming Hot
Mar. 2, 2012, 12:29 pm EDT – Innovative products, improved customer service and new efforts in Europe and India should keep the java giant growing for years to come.
Mattel Is Serious Fun for Investors
Feb. 24, 2012, 8:48 am EDT – The No. 1 toymaker's stock keeps rolling -- and its dividend keeps rising -- as it continues to keep the hit toys coming in markets around the world.
Why Illumina’s Future Remains Bright
Feb. 17, 2012, 9:15 am EDT – Rejection of Roche's takeover bid has cooled ILMN shares, but many expect Roche to step up its advances. If not, Illumina still has great growth prospects.
Blue Chip Growth
Independent Adviser for Vanguard Investors
Mutual Funds & ETFs